Cargando…

Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria

INTRODUCTION: Mosquito-borne infections are of global health concern because of their rapid spread and upsurge, which creates a risk for coinfections. DENV and ZIKV are transmitted by Aedes aegypti and A. albopictus and are prevalent in Nigeria and neighbouring countries. However, their seroprevalen...

Descripción completa

Detalles Bibliográficos
Autores principales: Asaga Mac, Peter, Tadele, Markos, Airiohuodion, Philomena E., Nisansala, Thilini, Zubair, Shaistha, Aigohbahi, Jude, Anyaike, Chukwuma, Velayudha, Raman, Kroeger, Axel, Panning, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970210/
https://www.ncbi.nlm.nih.gov/pubmed/37074313
http://dx.doi.org/10.1080/07853890.2023.2175903
_version_ 1784897876821803008
author Asaga Mac, Peter
Tadele, Markos
Airiohuodion, Philomena E.
Nisansala, Thilini
Zubair, Shaistha
Aigohbahi, Jude
Anyaike, Chukwuma
Velayudha, Raman
Kroeger, Axel
Panning, Marcus
author_facet Asaga Mac, Peter
Tadele, Markos
Airiohuodion, Philomena E.
Nisansala, Thilini
Zubair, Shaistha
Aigohbahi, Jude
Anyaike, Chukwuma
Velayudha, Raman
Kroeger, Axel
Panning, Marcus
author_sort Asaga Mac, Peter
collection PubMed
description INTRODUCTION: Mosquito-borne infections are of global health concern because of their rapid spread and upsurge, which creates a risk for coinfections. DENV and ZIKV are transmitted by Aedes aegypti and A. albopictus and are prevalent in Nigeria and neighbouring countries. However, their seroprevalence, burden, hidden endemicity and possible cocirculation are poorly understood in Nigeria. METHODS: We conducted a cross-sectional study of 871 participants from three regions of Nigeria. All serum samples were analysed using malaria RDT and the immunoblot molecular diagnostic assay recomLine Tropical Fever for the presence of arboviral antibody serological marker IgG (Mikrogen Diagnostik, Neuried, Germany) with DENV and ZIKV Nonstructural protein 1 (NS 1), DENV and ZIKV Equad (variant of the envelope protein with designated mutations to increase specificity), according to the manufacturer’s instructions. RESULTS: The overall IgG antibody seropositivity against DENV-flavivirus was 44.7% (389/871); 95% CI (41.41–47.99), while ZIKV-flavivirus was 19.2% (167/871); 95% CI (0.16–0.21), and DENV-ZIKV-flavivirus cocirculation antibody seropositivity was 6.2%5 (54/871); 95% CI (0.6–0.7) in the three study regions of Nigeria. The study cohort presented similar clinical signs and symptoms of flaviviruses (DENV and ZIKV) in all three study regions. CONCLUSION: This study highlighted an unexpectedly high antibody seropositivity, burden, hidden endemicity, and regional spread of mono- and co-circulating flaviviruses (DENV and ZIKV) in Nigeria. KEY MESSAGES: Dengue flavivirus sero-cross-reactivity drives antibody-dependent enhancement of ZIKV infection. Both viruses share common hosts (humans) and vectors (primarily Aedes aegypti), and are thus influenced by similar biological, ecological, and economic factors, resulting in epidemiological synergy. Additionally, the actual burden in epidemic and interepidemic periods is grossly or chronically unknown and underreported. Despite this trend and the potential public health threat, there are no reliable data, and little is known about these arboviral co-circulation infections.
format Online
Article
Text
id pubmed-9970210
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-99702102023-02-28 Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria Asaga Mac, Peter Tadele, Markos Airiohuodion, Philomena E. Nisansala, Thilini Zubair, Shaistha Aigohbahi, Jude Anyaike, Chukwuma Velayudha, Raman Kroeger, Axel Panning, Marcus Ann Med Infectious Diseases INTRODUCTION: Mosquito-borne infections are of global health concern because of their rapid spread and upsurge, which creates a risk for coinfections. DENV and ZIKV are transmitted by Aedes aegypti and A. albopictus and are prevalent in Nigeria and neighbouring countries. However, their seroprevalence, burden, hidden endemicity and possible cocirculation are poorly understood in Nigeria. METHODS: We conducted a cross-sectional study of 871 participants from three regions of Nigeria. All serum samples were analysed using malaria RDT and the immunoblot molecular diagnostic assay recomLine Tropical Fever for the presence of arboviral antibody serological marker IgG (Mikrogen Diagnostik, Neuried, Germany) with DENV and ZIKV Nonstructural protein 1 (NS 1), DENV and ZIKV Equad (variant of the envelope protein with designated mutations to increase specificity), according to the manufacturer’s instructions. RESULTS: The overall IgG antibody seropositivity against DENV-flavivirus was 44.7% (389/871); 95% CI (41.41–47.99), while ZIKV-flavivirus was 19.2% (167/871); 95% CI (0.16–0.21), and DENV-ZIKV-flavivirus cocirculation antibody seropositivity was 6.2%5 (54/871); 95% CI (0.6–0.7) in the three study regions of Nigeria. The study cohort presented similar clinical signs and symptoms of flaviviruses (DENV and ZIKV) in all three study regions. CONCLUSION: This study highlighted an unexpectedly high antibody seropositivity, burden, hidden endemicity, and regional spread of mono- and co-circulating flaviviruses (DENV and ZIKV) in Nigeria. KEY MESSAGES: Dengue flavivirus sero-cross-reactivity drives antibody-dependent enhancement of ZIKV infection. Both viruses share common hosts (humans) and vectors (primarily Aedes aegypti), and are thus influenced by similar biological, ecological, and economic factors, resulting in epidemiological synergy. Additionally, the actual burden in epidemic and interepidemic periods is grossly or chronically unknown and underreported. Despite this trend and the potential public health threat, there are no reliable data, and little is known about these arboviral co-circulation infections. Taylor & Francis 2023-02-22 /pmc/articles/PMC9970210/ /pubmed/37074313 http://dx.doi.org/10.1080/07853890.2023.2175903 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Infectious Diseases
Asaga Mac, Peter
Tadele, Markos
Airiohuodion, Philomena E.
Nisansala, Thilini
Zubair, Shaistha
Aigohbahi, Jude
Anyaike, Chukwuma
Velayudha, Raman
Kroeger, Axel
Panning, Marcus
Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria
title Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria
title_full Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria
title_fullStr Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria
title_full_unstemmed Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria
title_short Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria
title_sort dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in nigeria
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970210/
https://www.ncbi.nlm.nih.gov/pubmed/37074313
http://dx.doi.org/10.1080/07853890.2023.2175903
work_keys_str_mv AT asagamacpeter dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT tadelemarkos dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT airiohuodionphilomenae dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT nisansalathilini dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT zubairshaistha dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT aigohbahijude dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT anyaikechukwuma dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT velayudharaman dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT kroegeraxel dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria
AT panningmarcus dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria